Multi-Biomarker AMI Detection via Kinetic Segmentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting acute myocardial injury (AMI) are challenging, particularly in identifying high-risk patients who could benefit from early invasive approaches, as cardiac troponins rise slowly and small elevations are nonspecific and difficult to interpret.

Innovation Solution

A method involving the detection of cardiac troponin I (cTnI), fatty acid binding protein (FABP3), and ventricular myosin alkali light chain (MYL3) in biological samples, comparing their levels and rate of change to determine the presence, timing, and severity of AMI, allowing for earlier identification and differentiation between large and small myocardial injuries.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If cardiac troponin assays are used to detect AMI, then cardiac specificity is improved, but detection timing is delayed and small elevations are nonspecific

Engineering Contradiction:

Improvecardiac specificityVSAvoiddetection timing

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent segments the detection process into multiple time points (0, 30, and 60 minutes) and uses multiple biomarkers (cTnI, FABP3, MYL3) with different kinetic profiles. This segmentation allows early detection using FABP3 and MYL3 while maintaining cardiac specificity through the combination approach, resolving the contradiction between early detection timing and reliable cardiac specificity.

Inventive Principle:

Principle #1Segmentation

2Ease of operation

If single biomarker assays are used, then test simplicity is improved, but ability to differentiate injury severity is reduced

Engineering Contradiction:

Improvetest simplicityVSAvoidinjury severity differentiation

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent merges three biomarker assays (cTnI, FABP3, MYL3) into a combined detection system. The synergistic effect of these biomarkers with different release kinetics enables differentiation between large and small AMI events through their unique temporal patterns, while maintaining operational simplicity through a standardized multi-marker protocol.

Inventive Principle:

Principle #5Merging (Combining)

3Loss of time

If early detection methods are implemented, then intervention timing is improved, but false positive rate increases due to nonspecific elevations

Engineering Contradiction:

Improveintervention timingVSAvoidfalse positive rate

Core Design Contradiction:

Loss of timeVSReliability

Solution Approach 1:

The patent implements a feedback mechanism by comparing biomarker levels across multiple time points (0, 30, and 60 minutes) and analyzing the temporal patterns of change. This feedback approach distinguishes true AMI events showing characteristic kinetic patterns from nonspecific elevations, enabling early intervention while maintaining high reliability and reducing false positives.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS10690681B2Methods to detect myocardial injury and uses thereof

Publication Date: 2020.06.23 WASHINGTON UNIV IN SAINT LOUIS

AI summary

The present invention provides an accurate and reliable method to detect acute cardiovascular syndromes or disorders and to detect acute cardiovascular syndromes or disorders at earlier time points such that more aggressive interventions can be used in high risk subjects